ORGS
PINK Orgenesis Inc.$0.0700 ↓ -0.2800 (-80.00%) Trading Down from the previous close of $0.3500, and at the day’s high of $0.0700
- YTD change
- -53.33%
- vs 20-day SMA
- -85.48%
- vs 200-day SMA
- -81.93%
Price ranges
Price & Performance
-0.09 (-56.25%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 100.0% away from all-time highs of $168.0000
- ORGS is down 53% since the beginning of the year
- ORGS is down 36% over the past 12 months
- ORGS is down 83% over the past 1 month
- 0% of all ORGS investors are betting against ORGS
ORGS reads n/a: price sits below both the 20- and 200-day averages, the 12-month move is -93.0%.
- Previous minute
- +$0.0000
- Last hour
- +$0.0000
- Last 5 days
- -87.93%
- vs 8-day SMA
- -87.06%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies and services in the cell and gene therapy industry. It operates through the following segments: Octomera and Therapies. The Octomera segment refers to the point-of-care services. The Therapies segment is involved in therapeutic development operations. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
